Tagged with Medicine

Switzerland Michael Cobas Meyer of Eli Lilly Switzerland reveals how these are very exciting times for the company, particularly given an extremely rich pipeline in the areas of diabetes, oncology and bio-medicines; how the challenge will be to transition from their existing portfolio to new products; and why Lilly´s focus is…

Luxembourg Rudi Balling discusses his distinguished career in the life sciences, the LCSB’s mission, and Luxembourg’s burgeoning reputation as a biomedicine, interdisciplinary research, and scientific innovation hub. Earlier this year you were awarded the ‘Ordre de Mérite’ for your longstanding contribution to science by the Luxembourg government following a distinguished career…

Pharma Dr. Leisha Daly, Janssen Ireland country director and president of the Irish Pharmaceutical Healthcare Association (IPHA) discusses her presidency and the conclusion of a four-year agreement between IPHA and the Irish government on the supply of medicine. She then highlights Janssen’s leadership in Ireland in terms of ‘open-innovation’ and ‘beyond-the-pill’…

Health Professor Jürg Utzinger of the Swiss Tropical and Public Health Institute (Swiss TPH) emphasizes the importance of partnerships and sharing information for improving population health locally, nationally, and internationally. He comments on Swiss innovation, the clinical trials conducted at Swiss TPH, and the current publicity around the Zika virus.   You…

Pharma Daniel Breitenstein, VP and GM of GSK Switzerland, discusses the benefits of GSK’s three-part transaction with Novartis; the importance of respiratory diseases and vaccines for future success; and how the company has changed its business model by no longer paying for physicians to speak on their behalf, setting in process…

Health Alberto Hechanova, president of the Drugstore Association of the Philippines (DSAP), discusses the competitive landscape of the country, highlighting the main challenges and opportunities for independent drugstores. In addition, he explains why being a member of the association can impact business success. Mr Hechanova, could you please introduce yourself and…

Pharma The expansion of universal healthcare coverage and significant growth in the use and acceptance of generics across the Philippines pose a significant challenge to the innovative medicines industry but also offers a wealth of opportunities for both international and domestic players. The Philippines now utilizes low-cost generics more than any…

Health Tackling both obesity and diabetes is a primary objective of the National Academy of Medicine of Mexico and requires a holistic, multidisciplinary approach, according to Dr. Graue Wiechers, president of the National Academy of Medicine and rector at UNAM (National Autonomous University of Mexico), the largest university in Latin America.…

Pharma Servier GM Florent Darchez, reveals how he turned around a Mexico affiliate that was losing market share to achieve and impressive sales growth of 30 percent a year. Darchez also shares his vision for further strengthening his organization.  We see that in 2016, around 60 percent of Servier revenues derived…

Pharma The founder of Contipro elaborates on his success story which positions his company as one of the three leading suppliers of hyaluronic acid worldwide. Furthermore, he reviews the success of the recently opened subsidiary in France and identifies the next target markets for Contipro’s international expansion. Hyaluronic acid seems to…

Pharma Building on the continuous improvements of the Federal Commission for the Protection Against Sanitary Risk (Cofepris) over the last few years, its recently-appointed Federal Commissioner Julio Sánchez y Tépoz reveals his strategy to further strengthen and develop the Commission’s processes and international leadership, and foster a more transparent, technical, efficient…

Pharma Anita Ordog, GM of Angelini Hungary, discusses the affiliate’s history in the country, their expanding OTC and specialty products portfolio, targeted marketing and sales strategies, and Angelini’s challenging entrance into the Hungarian pharmaceutical market. To begin, could you share some insights into your background and tell us how you came…